Literature DB >> 12064791

Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.

Melissa D Murphy1, Hugo R Rosen, Gail I Marousek, Sunwen Chou.   

Abstract

Interferon (IFN) and ribavirin combination therapy for chronic hepatitis C virus (HCV) infection yields a sustained response rate of only approximately 40%. Previous studies have linked IFN responsiveness to viral sequence variation in parts of the E2 and NS5A genes, but this remains controversial. We studied pretreatment sera from 28 subjects (23 with HCV genotype 1a) who received high-dose IFN induction followed by IFN-ribavirin combination therapy. Serum HCV sequences were amplified and compared from 14 responders with undetectable HCV RNA 24 weeks after therapy and 11 nonresponders (excluding three who dropped out of the study). Analysis included the E2 PKR eIF-2alpha phosphorylation homology domain (PePHD, codons 659-670), where the sequence was well conserved, and codons 2001-2420 of NS5A. In NS5A, the proposed PKR binding domain (codons 2209-2274), containing the putative IFN sensitivity determining region (ISDR, codons 2209-2248), showed too little variation among subjects to differentiate responders and nonresponders. NS5A codons 2356-2385 (which includes the V3 region) exhibited more variation. Here, six of 12 genotype 1a responders showed four or more amino acid changes from the prototype HCV-1 sequence, as compared with one of eight nonresponders, but this fell short of statistical significance (P = 0.16). NS5A sequences from posttreatment sera were examined in six nonresponders to look for selection of treatment-resistant viral subpopulations, but no consistent change was detected. In conclusion, our results indicate that the sequences of the ISDR, the PKR-binding domain, and the PePHD are unlikely to have predictive value for IFN treatment success in those infected with HCV genotype 1a. However, the finding of greater variability among treatment responders in the carboxy end of NS5A suggests that the V3 region merits further investigation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12064791     DOI: 10.1023/a:1015349924116

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  Interferon plus ribavirin for chronic hepatitis C.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1999-06-04       Impact factor: 1.909

2.  Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis.

Authors:  S Murashima; T Ide; I Miyajima; R Kumashiro; T Ueno; S Sakisaka; M Sata
Journal:  Scand J Infect Dis       Date:  1999

3.  The epidemic behavior of the hepatitis C virus.

Authors:  O G Pybus; M A Charleston; S Gupta; A Rambaut; E C Holmes; P H Harvey
Journal:  Science       Date:  2001-06-22       Impact factor: 47.728

4.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

5.  Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNA.

Authors:  Y Arase; K Ikeda; K Chayama; N Murashima; A Tsubota; Y Suzuki; S Saitoh; M Kobayashi; M Kobayashi; M Kobayashi; H Kumada
Journal:  Intern Med       Date:  1999-06       Impact factor: 1.271

6.  Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection.

Authors:  G Squadrito; M E Orlando; I Cacciola; M G Rumi; M Artini; A Picciotto; O Loiacono; R Siciliano; M Levrero; G Raimondo
Journal:  J Hepatol       Date:  1999-06       Impact factor: 25.083

7.  Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus.

Authors:  R T Chung; A Monto; J L Dienstag; L M Kaplan
Journal:  J Med Virol       Date:  1999-08       Impact factor: 2.327

8.  Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response.

Authors:  C Sarrazin; T Berg; J H Lee; B Rüster; B Kronenberger; W K Roth; S Zeuzem
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

9.  Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.

Authors:  M J Gale; M J Korth; N M Tang; S L Tan; D A Hopkins; T E Dever; S J Polyak; D R Gretch; M G Katze
Journal:  Virology       Date:  1997-04-14       Impact factor: 3.616

10.  Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment.

Authors:  J Odeberg; Z Yun; A Sönnerborg; O Weiland; J Lundeberg
Journal:  J Med Virol       Date:  1998-09       Impact factor: 2.327

View more
  18 in total

Review 1.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

2.  Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.

Authors:  Mina Nakagawa; Naoya Sakamoto; Mayumi Ueyama; Kaoru Mogushi; Satoshi Nagaie; Yasuhiro Itsui; Seishin Azuma; Sei Kakinuma; Hiroshi Tanaka; Nobuyuki Enomoto; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

Review 3.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

4.  Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Joonho Yoon; Jong In Lee; Soon Koo Baik; Kwang Ho Lee; Joon Hyung Sohn; Hyean Woo Lee; Jun Namkung; Sei Jin Chang; Jong Whan Choi; Hyun Won Kim; Byung-Il Yeh
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

Review 5.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

Review 6.  Drug resistance in antiviral treatment for infections with hepatitis B and C viruses.

Authors:  Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527

7.  Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences.

Authors:  M Pascu; P Martus; M Höhne; B Wiedenmann; U Hopf; E Schreier; T Berg
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

8.  Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.

Authors:  Celia Perales; Nathan M Beach; Isabel Gallego; Maria Eugenia Soria; Josep Quer; Juan Ignacio Esteban; Charles Rice; Esteban Domingo; Julie Sheldon
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

9.  Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response.

Authors:  Cíntia Bittar; Ana Carolina G Jardim; Lilian H T Yamasaki; Artur T L de Queiróz; Claudia M A Carareto; João Renato R Pinho; Isabel Maria V G de Carvalho-Mello; Paula Rahal
Journal:  BMC Infect Dis       Date:  2010-02-23       Impact factor: 3.090

10.  Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*.

Authors:  H J Yuan; M Jain; K K Snow; M Gale; W M Lee
Journal:  J Viral Hepat       Date:  2009-07-28       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.